Oxford BioDynamics installs new SVP of Commercial Development
Oxford BioDynamics, a biotech focused on the discovery and development of novel epigenetics biomarkers, has announced the appointment of Martin Reeves as Senior Vice President of Commercial Development. The company is based in Oxford but Reeves will work remotely from the US, taking up the role this month.
Reeves comes to the company with experience working for Teva Pharmaceuticals, where he performed the role of Head of Business Development for Global Branded Products. He also held the role of Vice President of Business Development and Strategic Planning at Cephalon, where he worked for 14 years, prior to its takeover by Teva.
Christian Hoyer Millar, CEO of Oxford BioDynamics said: "We are delighted that Martin will be joining the Company as Senior Vice President of Commercial Development. His considerable experience in business development within the sector will be a great asset to Oxford BioDynamics as we look to leverage IP licensing opportunities with our award-winning, proprietary technology platform, EpiSwitch."